The goal is to identify targets for new drugs, and it is known that drugs based on specific genes or mutations often have the best chance of success - look up, for example PCSK9 inhibitors. 23andMe, along with having genetic information, have very, very detailed phenotypic information on the people they sequence, which they collect in the form of surveys. This in turn lets them do GWAS-like analyses better than anyone else on earth. These GWAS hits can in turn go through a pipeline to find those genes which might confer protection, or susceptibility, to a particular disease. Then, it's up to GSK to make a molecule to mimic or inhibit that effect.
What should be clear here is that 23andMe is NOT giving GSK access to their data. They are giving them leads.
Source: work in research R&D in biopharma (with a particular interest in genetics)
23andmes database's best advantage is probably studying things like genetic basis of mild to moderate anxiety and depression as those diseases are probably more prevalent in their population than others. Plus those are complex polygenic traits so each individual gene would have a small effect size, so a big database like 23andmes would be useful
However that isn't great for drug discovery because drugs only hit one target. A bunch of genes with small effect sizes won't support much of a drug dev program
I may be wrong as I'm not familiar w 23andmes database but these are my deductions from what I do know
"If at any time you are no longer interested in participating in our Services, you may delete your 23andMe account and personal data, directly within your Account Settings."
source: https://customercare.23andme.com/hc/en-us/articles/212170688...
I agree sort of, but how interesting is it that many people seem to really care when it’s their immutable genetic information to 23&Me - but when it’s their habitual and social information to Google or Facebook they seem care a lot less.
You should have assumed when you spit in the tube that you waived all rights to protecting your genetic data.
I'm not saying they should be allowed to use it however, including selling, but I'm saying when you spit in a tube and send your DNA to a company... you should kinda assume the worst.
"Blinded to patient identity" is true, but it can be relatively easy to re-identify these individuals using this data. So this data has your identity intertwined with potentially very private information. Some people intuitively desire to be as cautious as possible with their genetic information, and there is good reason for caution. Worst case it somehow ends up on the black market. You can't change your DNA, so if it gets out, there is no turning back.
As mentioned, 23andme uses genotyping not sequencing so it's unclear whether there data is that valuable for target discovery. and while it's not unprecedented for pharma to spend $300M for a target id deal, it is quite rare
I think your point still stands though, your genotype is still identifying information and should be safeguarded.
https://customercare.23andme.com/hc/en-us/articles/202904600...
Their prices are low for the "consumer" (product). The $300 million GSK deal is an example of how they can make real money.
yet
There's probably already some mad biohacker out there doing this as we speak and being called a loon by everyone who knows them.
Sequencing studies really don't show this.
Sequencing finds rare variants. GWAS finds loci with common variants. We know that for many common diseases, the population-level variability due to rare variants is small. If you want to find drug targets, there is plenty of reason to use both approaches.
The other way, and where I suspect the bulk of the $300M/4yrs is going, is in recruiting patients for clinical trials. GSK can tell 23andMe that they need 150 patients living near metropolitan centers who have indicated they suffer from X disease, and don't have Y mutation. This could drastically reduce the cost of recruiting for Phase 2 trials (though it may skew the patient populations in ways we haven't really had to deal with before). <edit> If I remember correctly, 23andMe contacts these potential patients to ask if they're interested in the GSK trial, then refers them to contact the GSK clinical trial site. They don't just give your phone number to GSK </edit>
I guess I'm not really sure what the panic is about. First, every step is opt-in. Second, the data provided en masse is blinded to patient identity and industry standard is to disincentivize unblinding the data. Am I too close to and brainwashed by the industry to see what's wrong here?